257 related articles for article (PubMed ID: 32660417)
1. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.
Hsu HY; Lin CJ; Lee YS; Wu TH; Chien KL
BMC Cardiovasc Disord; 2020 Jul; 20(1):334. PubMed ID: 32660417
[TBL] [Abstract][Full Text] [Related]
2. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
[TBL] [Abstract][Full Text] [Related]
3. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
5. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
6. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
[TBL] [Abstract][Full Text] [Related]
7. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
[TBL] [Abstract][Full Text] [Related]
9. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.
Wang N; Fulcher J; Abeysuriya N; Park L; Kumar S; Di Tanna GL; Wilcox I; Keech A; Rodgers A; Lal S
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):36-49. PubMed ID: 31862150
[TBL] [Abstract][Full Text] [Related]
10. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.
Navarese EP; Andreotti F; Raggi P; Kolodziejczak M; Buffon A; Bliden K; Tantry U; Kubica J; Sardella G; Lauten A; Agewall S; Gurbel PA; Brouwer MA
Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):47-54. PubMed ID: 30247574
[TBL] [Abstract][Full Text] [Related]
11. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Zhang XL; Lan RF; Zhang XW; Xu W; Wang L; Kang LN; Xu B
J Am Heart Assoc; 2019 Aug; 8(16):e012428. PubMed ID: 31411090
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
[TBL] [Abstract][Full Text] [Related]
13. Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.
Wang Q; Liang C
J Cardiovasc Pharmacol; 2020 Dec; 76(6):658-670. PubMed ID: 33002965
[TBL] [Abstract][Full Text] [Related]
14. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice.
Sinning D; Landmesser U
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):71-76. PubMed ID: 28618905
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
18. Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Jin S; Nie X; Li Y; Yuan J; Cui Y; Zhao L
Clin Ther; 2021 Jul; 43(7):e217-e229. PubMed ID: 34092409
[TBL] [Abstract][Full Text] [Related]
19. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence.
Stauffer ME; Weisenfluh L; Morrison A
Vasc Health Risk Manag; 2013; 9():671-80. PubMed ID: 24204156
[TBL] [Abstract][Full Text] [Related]
20. Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis.
Ennezat PV; Guerbaai RA; Maréchaux S; Le Jemtel TH; François P
J Cardiovasc Pharmacol; 2023 Jan; 81(1):35-44. PubMed ID: 36027598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
